Effectiveness and safety of oral and intralesional tranexamic acid in treatment of melasma

Not Applicable

Completed

• Conditions: Health Condition 1: L811- ChloasmaHealth Condition 2: O- Medical and Surgical

• Registration Number: CTRI/2021/08/035350
• Lead Sponsor: Department of Dermatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-05-27
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 42

Inclusion Criteria

1. Patients with clinical diagnosis of melasma.

2. Patients above the age of 18 years and below the age of 50 years.

Exclusion Criteria

1. Patients with a history of bleeding disorders

2. Patient taking oral anticoagulants, hormonal drugs like estrogen, progesterone, oral contraceptive pills and other female hormonal analogues.

3. Patients with past history of thrombotic disease like DVT.

4. Patients with family history of thrombotic disease.

5. Patients with known allergy to tranexamic acid.

6. Pregnant and lactation mothers.

7. Patients using photosensitizing drugs such as nonsteroidal anti-inflammatory drugs, tetracycline, spironolactone, phenytoin, carbamazepine, use of other depigmenting oral or topical agents.

8. Patients with any other facial dermatoses.

9. Patients with a history of any treatment for melasma in the past 6 months.

10. Patients with significant systemic illness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare the clinical efficacy of oral and intralesional tranexamic acid in treatment of melasma.Timepoint: at 4, 8 and 12 weeks than follow up at 16, 20 and 24 weeks

Secondary Outcome Measures

Name	Time	Method
OT APPLICABLETimepoint: NOT APPLICABLE